BioLife Solutions (STU:BJX1) Cyclically Adjusted Book per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BJX1 BioLife Solutions Inc STU:BJX1
73 GF Score
Price €29.40
GF Value €25.24
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Cyclically Adjusted Book per Share?

BioLife Solutions STU:BJX1 +1.38% 73 Cyclically Adjusted Book per Share is €0.00 as of Jun. 2026. GuruFocus rates STU:BJX1 with a GF Score™ of 73/100 and a GF Value™ of €25.24 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioLife Solutions's adjusted book value per share for the three months ended in Jun. 2026 was €7.396. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioLife Solutions's average Cyclically Adjusted Book Growth Rate was 15.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 23.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 62.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioLife Solutions was 121.70% per year. The lowest was -90.70% per year. And the median was -6.30% per year.

As of today (2026-08-07), BioLife Solutions's current stock price is €29.40. BioLife Solutions's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €0.00. BioLife Solutions's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioLife Solutions was 242.89. The lowest was 2.28. And the median was 5.41.


BioLife Solutions  (STU:BJX1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioLife Solutions was 242.89. The lowest was 2.28. And the median was 5.41.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioLife Solutions Cyclically Adjusted Book per Share Related Terms


BioLife Solutions Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Cyclically Adjusted Book per Share Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 2.87 4.00 4.91 5.07

BioLife Solutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.60 4.63 5.07 5.26 0.00

STU:BJX1 vs AZTA, KMTS, STAA: Cyclically Adjusted Book per Share Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Cyclically Adjusted PB Ratio falls into.


STU:BJX1
73GF Score
BioLife Solutions Inc STU:BJX1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLife Solutions's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.396/333.9520*333.9520
=7.396

Current CPI (Jun. 2026) = 333.9520.

BioLife Solutions Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.430 241.428 0.595
201612 0.233 241.432 0.322
201703 0.201 243.801 0.275
201706 0.460 244.955 0.627
201709 0.454 246.819 0.614
201712 0.608 246.524 0.824
201803 0.600 249.554 0.803
201806 1.045 251.989 1.385
201809 2.064 252.439 2.730
201812 0.693 251.233 0.921
201903 2.098 254.202 2.756
201906 2.167 256.143 2.825
201909 3.435 256.759 4.468
201912 1.878 256.974 2.441
202003 2.897 258.115 3.748
202006 3.617 257.797 4.685
202009 4.937 260.280 6.334
202012 5.106 260.474 6.546
202103 5.214 264.877 6.574
202106 9.255 271.696 11.376
202109 10.035 274.310 12.217
202112 10.117 278.802 12.118
202203 10.264 287.504 11.922
202206 9.170 296.311 10.335
202209 9.655 296.808 10.863
202212 8.027 296.797 9.032
202303 7.726 301.836 8.548
202306 7.482 305.109 8.189
202309 7.098 307.789 7.701
202312 6.855 306.746 7.463
202403 6.713 312.332 7.178
202406 6.477 314.175 6.885
202409 6.343 315.301 6.718
202412 7.104 315.605 7.517
202503 6.860 319.799 7.164
202506 6.291 322.561 6.513
202509 6.283 324.800 6.460
202512 6.589 324.054 6.790
202603 6.595 330.213 6.670
202606 7.396 333.952 7.396

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.00 mean?
BioLife Solutions (STU:BJX1) has a Cyclically Adjusted Book per Share of €0.00 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioLife Solutions and its competitors.
Is BioLife Solutions' Cyclically Adjusted Book per Share too high?
BioLife Solutions' current Cyclically Adjusted Book per Share is €0.00. Overall, BioLife Solutions has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Cyclically Adjusted Book per Share compare to AZTA and KMTS?
BioLife Solutions' Cyclically Adjusted Book per Share of €0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current Cyclically Adjusted Book per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (STU:BJX1) is currently considered Modestly Overvalued. The stock's GF Value™ is €25.24, compared to a current price of €29.40 — trading 16.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.00. BioLife Solutions' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BioLife Solutions (STU:BJX1), the current Cyclically Adjusted Book per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (STU:BJX1) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of €29.40 is trading 16.5% above its estimated GF Value™ of €25.24. GuruFocus considers BioLife Solutions to be Modestly Overvalued.

Key valuation signals for STU:BJX1:

  • Cyclically Adjusted Book per Share: €0.00
  • GF Value™: €25.24 vs. price of €29.40 (16.5% above fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the STU:BJX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioLife Solutions Business Description

Other Exchanges BLFS:USABJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
73GF Score

Get the complete analysis for STU:BJX1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.40
Price
€25.24
GF Value